SenesTech Inc (NASDAQ:SNES) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price target of $1.93 for the company, according to Zacks. Zacks has also given SenesTech an industry rank of 141 out of 255 based on the ratings given to its competitors.
In related news, insider Cheryl Ann Dyer sold 40,000 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $1.19, for a total value of $47,600.00. Following the completion of the transaction, the insider now directly owns 391,165 shares of the company’s stock, valued at approximately $465,486.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 52,000 shares of company stock valued at $58,160. Company insiders own 10.91% of the company’s stock.
Shares of NASDAQ:SNES traded up $0.05 during trading on Friday, reaching $0.76. The stock had a trading volume of 92,500 shares, compared to its average volume of 93,218. SenesTech has a 52 week low of $0.55 and a 52 week high of $1.95. The stock has a market capitalization of $20.33 million, a PE ratio of -1.21 and a beta of 1.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.73 and a quick ratio of 2.60. The business’s 50-day moving average price is $0.87 and its 200 day moving average price is $1.31.
SenesTech (NASDAQ:SNES) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. SenesTech had a negative net margin of 3,432.63% and a negative return on equity of 169.12%. The company had revenue of $0.02 million during the quarter. Analysts forecast that SenesTech will post -0.15 EPS for the current year.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
See Also: Green Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.